Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more